Collagen-binding ⁶⁸Ga-CBP8 PET/MR in Deep Pelvic Endometriosis: First-in-human Application.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2026-07-14 DOI:10.1007/s11307-026-02125-5

Antonino Andrea Blandino, Peter Caravan, Anuradha S Shenoy-Bhangle, Peter R Movilla, Elio Quiros, Mario V Russo, Michael J Misialek, Liran Domachevsky, Leo L Tsai, Onofrio Antonio Catalano

{"title":"Collagen-binding ⁶⁸Ga-CBP8 PET/MR in Deep Pelvic Endometriosis: First-in-human Application.","authors":"Antonino Andrea Blandino, Peter Caravan, Anuradha S Shenoy-Bhangle, Peter R Movilla, Elio Quiros, Mario V Russo, Michael J Misialek, Liran Domachevsky, Leo L Tsai, Onofrio Antonio Catalano","doi":"10.1007/s11307-026-02125-5","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the feasibility of collagen-binding ⁶⁸Ga-CBP8 PET/MR for the noninvasive detection of deep infiltrating endometriosis.Material and methods: A single-case exploratory application of ⁶⁸Ga-CBP8 PET/MR was conducted in a patient with endometriosis as a preliminary step toward a larger IRB-approved prospective study. Imaging was performed 60 min after intravenous administration of ⁶⁸Ga-CBP8. Fused PET/MR images were qualitatively assessed for focal tracer uptake exceeding background. Surgical pathology, assessed in a blinded fashion, served as the reference standard.Results: A 32-year-old woman with history of endometriosis completed the examination without adverse events. PET/MR demonstrated focal ⁶⁸Ga-CBP8 uptake corresponding on MR to a T2-hypointense plaque located between the left adnexa and the sigmoid colon, suspicious for deep pelvic endometriosis with bowel involvement. Surgical pathology confirmed endometriosis infiltrating the colonic muscularis mucosae and pericolonic tissue with dense fibrosis.Conclusion: ⁶⁸Ga-CBP8 PET/MR is a feasible and promising technique to noninvasively detect deep infiltrating endometriosis, warranting validation in larger prospective studies.Trial registration: ClinicalTrials.gov, NCT06377553. Date of first enrollment: February 5, 2025. Registered April 22, 2024.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-026-02125-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the feasibility of collagen-binding ⁶⁸Ga-CBP8 PET/MR for the noninvasive detection of deep infiltrating endometriosis.

Material and methods: A single-case exploratory application of ⁶⁸Ga-CBP8 PET/MR was conducted in a patient with endometriosis as a preliminary step toward a larger IRB-approved prospective study. Imaging was performed 60 min after intravenous administration of ⁶⁸Ga-CBP8. Fused PET/MR images were qualitatively assessed for focal tracer uptake exceeding background. Surgical pathology, assessed in a blinded fashion, served as the reference standard.

Results: A 32-year-old woman with history of endometriosis completed the examination without adverse events. PET/MR demonstrated focal ⁶⁸Ga-CBP8 uptake corresponding on MR to a T2-hypointense plaque located between the left adnexa and the sigmoid colon, suspicious for deep pelvic endometriosis with bowel involvement. Surgical pathology confirmed endometriosis infiltrating the colonic muscularis mucosae and pericolonic tissue with dense fibrosis.

Conclusion: ⁶⁸Ga-CBP8 PET/MR is a feasible and promising technique to noninvasively detect deep infiltrating endometriosis, warranting validation in larger prospective studies.

Trial registration: ClinicalTrials.gov, NCT06377553. Date of first enrollment: February 5, 2025. Registered April 22, 2024.

查看原文本刊更多论文

胶原结合⁶⁸Ga-CBP8 PET/MR在深盆腔子宫内膜异位症中的首次应用。

目的：探讨胶原结合⁶⁸Ga-CBP8 PET/MR无创检测深浸润性子宫内膜异位症的可行性。材料和方法：在一名子宫内膜异位症患者中进行了单例26⁸Ga-CBP8 PET/MR的探索性应用，作为一项更大规模的经irb批准的前瞻性研究的初步步骤。在静脉注射6⁸Ga-CBP8后60分钟进行影像学检查。融合PET/MR图像定性评估焦示踪剂摄取超过背景。手术病理，以盲法评估，作为参考标准。结果：32岁，子宫内膜异位症患者，无不良反应。PET/MR显示局灶性26⁸Ga-CBP8摄取，MR显示位于左附件和乙状结肠之间的t2 -低信号斑块，怀疑深盆腔子宫内膜异位症伴肠道受累。手术病理证实子宫内膜异位症浸润结肠粘膜肌层及结肠周围组织伴致密纤维化。结论：26⁸Ga-CBP8 PET/MR是一种可行且有前景的无创检测深浸润性子宫内膜异位症的技术，值得在更大规模的前瞻性研究中验证。试验注册：ClinicalTrials.gov, NCT06377553。首次入学日期：2025年2月5日。注册于2024年4月22日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.